Plain-English translation of NCT07571174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a follow-up study for people with ALS who already completed an earlier trial of , a new medication delivered directly into the spinal fluid through injections. Researchers want to understand how safe this medication is when given over a longer time period and how well patients tolerate it. The study will track your health and any side effects for about 96 weeks.
ALS is a serious condition where nerve cells gradually stop working, causing muscle weakness and paralysis. Early testing of this medication showed promise, but researchers need to follow patients for a longer time to make sure the treatment remains safe and that it doesn't cause unexpected problems down the road.
You likely qualify if…
You likely don't qualify if…
As a participant, you would continue to receive the same medication delivered through spinal injections as you received in the earlier study, but for a longer follow-up period of about 96 weeks. You would visit the study site regularly so doctors can monitor your health, check for any side effects, and see how you are responding to the treatment over time. The study team will carefully track your safety and how well you tolerate the medication.
AI-generated summary from trial data · Aug 27, 2026 · Not medical advice
Belgium
Canada
Germany